Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine plus lidocaine for prevention of postoperative acute kidney injury after colorectal cancer surgery
ChiCTR2500103256Phase 4Recruiting
- Sponsor
- Mianyang Central Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in acute kidney failure (AKF) comparing Control arm (lidocaine only) with Experimental arm (esketamine + lidocaine) (2 arms). Primary endpoint: Incidence of postoperative acute kidney injury (PO-AKI). Started May 2025; status: recruiting.
02
Drugs
esketaminelidocaine
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on ChiCTR2500103256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103256.